Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neuland Laboratories Limited (NEULANDLAB.NS)
INR19,114.00
+115.00 (+0.61%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Phoenix IVY Building 500033
Hyderabad, IN
Hyderabad, IN
CEO
Davuluri Saharsh Rao
Website
neulandlabs.com
IPO
2008-10-13
ISIN INE794A01010
Also trades on
Bombay Stock Exchange · NEULANDLAB.BO (INR)
National Stock Exchange of India · NEULANDLAB.NS (INR)
Description
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR19,114.00
+115.00 (+0.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
59.9K
Beta
-0.32
Float Shares
7.13M
Free Float %
55.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.98% | -4.56% | +13.68% | +26.36% | -4.22% | +8.71% | +31.06% | +454.53% | +695.15% | +2,199.55% | +14,793.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
19,114.00
DCF (Unlevered)
7,323.22
-61.7%
DCF (Levered)
12,181.42
-36.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
13.60
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+41.0% ★ Q1'26: +171.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+39.9% ★ Q1'26: +664.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.5% Q1'26: -26.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+23.9% ★ Q1'26: +36.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+19.7% ★ Q1'26: +45.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.52× Q1'26: 0.25× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 4 Rev. Ana. 4 EPS Ana. |
Mar 2028 2 Rev. Ana. 3 EPS Ana. |
Mar 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.66B
est: 5.11B (-8.9%)
|
4.69B
est: 4.93B (-4.8%)
|
5.10B
est: 5.20B (-1.9%)
|
5.66B
est: 5.83B (-2.9%)
|
5.11B
est: 5.19B (-1.5%)
|
6.59B
est: 6.59B (+0.0%)
|
7.39B
est: 7.73B (-4.4%)
|
9.18B
est: 9.24B (-0.6%)
|
9.23B
est: 9.51B (-2.9%)
|
11.61B
est: 10.42B (+11.4%)
|
15.16B
est: 15.69B (-3.4%)
|
14.34B
est: 15.39B (-6.8%)
|
18.88B
18.24B – 19.34B
+22.7% YoY
|
23.05B
21.42B – 24.88B
+22.1% YoY
|
26.94B
25.03B – 29.07B
+16.8% YoY
|
34.22B
31.80B – 36.94B
+27.0% YoY
|
| EBITDA |
664.80M
est: 1.18B (-43.8%)
|
583.69M
est: 1.14B (-48.8%)
|
734.91M
est: 310.02M (+137.1%)
|
1.01B
est: 492.91M (+104.8%)
|
490.98M
est: 645.10M (-23.9%)
|
561.12M
est: 291.17M (+92.7%)
|
1.00B
est: 394.07M (+154.7%)
|
1.58B
est: 499.54M (+215.9%)
|
1.41B
est: 558.27M (+152.1%)
|
2.79B
est: 590.37M (+372.5%)
|
4.72B
est: 642.20M (+634.8%)
|
4.18B
est: 3.59B (+16.3%)
|
4.41B
4.26B – 4.52B
+22.7% YoY
|
5.38B
5.00B – 5.81B
+22.1% YoY
|
6.29B
5.84B – 6.79B
+16.8% YoY
|
7.99B
7.42B – 8.62B
+27.0% YoY
|
| EBIT |
515.41M
est: 954.40M (-46.0%)
|
430.49M
est: 920.08M (-53.2%)
|
577.49M
est: 601.56M (-4.0%)
|
817.18M
est: 731.30M (+11.7%)
|
269.94M
est: 790.50M (-65.9%)
|
302.49M
est: 363.20M (-16.7%)
|
690.76M
est: 443.67M (+55.7%)
|
1.18B
est: 797.26M (+48.2%)
|
916.96M
est: 890.99M (+2.9%)
|
2.26B
est: 942.22M (+140.0%)
|
4.13B
est: 1.02B (+302.5%)
|
3.52B
est: 2.89B (+21.7%)
|
3.55B
3.43B – 3.64B
+22.7% YoY
|
4.34B
4.03B – 4.68B
+22.1% YoY
|
5.07B
4.71B – 5.47B
+16.8% YoY
|
6.44B
5.98B – 6.95B
+27.0% YoY
|
| Net Income |
268.07M
est: 425.53M (-37.0%)
|
159.47M
est: 447.64M (-64.4%)
|
273.25M
est: 276.78M (-1.3%)
|
468.65M
est: 308.83M (+51.7%)
|
120.63M
est: 420.03M (-71.3%)
|
164.42M
est: 151.04M (+8.9%)
|
162.11M
est: 192.85M (-15.9%)
|
806.31M
est: 178.79M (+351.0%)
|
638.22M
est: 199.82M (+219.4%)
|
1.64B
est: 211.30M (+673.9%)
|
3.00B
est: 229.85M (+1,205.5%)
|
2.60B
est: 2.46B (+5.6%)
|
3.12B
3.07B – 3.14B
+26.5% YoY
|
4.48B
4.04B – 5.36B
+43.7% YoY
|
5.67B
5.15B – 6.25B
+26.5% YoY
|
6.58B
5.98B – 7.26B
+16.2% YoY
|
| SGA |
299.97M
est: 364.69M (-17.7%)
|
644.54M
est: 351.57M (+83.3%)
|
847.25M
est: 858.00M (-1.3%)
|
1.01B
est: 1.35B (-25.0%)
|
1.06B
est: 1.21B (-12.5%)
|
1.13B
est: 1.94B (-41.8%)
|
1.24B
est: 1.89B (-34.4%)
|
1.50B
est: 2.11B (-28.6%)
|
1.83B
est: 2.35B (-22.2%)
|
2.03B
est: 2.49B (-18.6%)
|
2.58B
est: 2.71B (-4.8%)
|
2.73B
est: 2.76B (-1.0%)
|
3.39B
3.27B – 3.47B
+22.7% YoY
|
4.14B
3.85B – 4.47B
+22.1% YoY
|
4.84B
4.49B – 5.22B
+16.8% YoY
|
6.14B
5.71B – 6.63B
+27.0% YoY
|
| EPS |
33.84
est: 33.17 (+2.0%)
|
18.67
est: 34.89 (-46.5%)
|
30.76
est: 33.08 (-7.0%)
|
42.01
est: 47.08 (-10.8%)
|
10.81
est: 19.40 (-44.3%)
|
13.06
est: 12.83 (+1.8%)
|
12.63
est: 27.70 (-54.4%)
|
62.85
est: 63.47 (-1.0%)
|
49.74
est: 52.70 (-5.6%)
|
127.45
est: 79.05 (+61.2%)
|
233.89
est: 242.22 (-3.4%)
|
202.74
est: 191.97 (+5.6%)
|
242.81
239.28 – 244.98
+26.5% YoY
|
349.03
314.84 – 418.14
+43.7% YoY
|
441.63
401.07 – 487.20
+26.5% YoY
|
513.00
465.88 – 565.95
+16.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.05B
OE per share TTM
-159.67
Owner's Yield
-0.93%
Maintenance CapEx ratio
78.46%
Maint CapEx / Avg PPE
46.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews India Active ETF INDE INDE | 3.97% | 706.0K | 0.79% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 387.7K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 171.9K | 0.48% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 28.7K | 0.24% |
| 5 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 28.7K | 0.24% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 30.7K | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 92.6K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 49.8K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 21.9K | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 2.5K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.94M
Shares Outstanding
12.83M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Davuluri Sucheth Rao | Executive Vice Chairman | 101M | male |
| Davuluri Rama Mohan Rao | Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 101M | — |
| Davuluri Saharsh Rao | CEO & MD | 101M | male |
| Sarada Bhamidipati | Company Secretary & Compliance Officer | — | female |
| Sharadsrikar V. Kotturi | Chief Scientific Officer & Member of Scientific Advisory Board | — | — |
| Sudheer Yarabolu | Global Head Sales & BD | — | male |
| Abhijit Majumdar | Chief Financial Officer | — | male |
| Sundar Narsimhan | Chief Procurement Officer | — | male |
| Ajitabh Singh | Chief Information Officer | — | male |
| Hemchandra Peruvelli | Chief Human Resources Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NEULANDLAB.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
